background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

PROTEASOME

The ubiquitin proteasome pathway is the main pathway for intracellular protein degradation and is essential for normal cell function.1 More than 80% of cellular proteins are degraded through this pathway, including those involved in cell cycle, apoptosis, DNA repair, and protein quality control.2 Inhibition of the proteasome stimulates apoptotic factors and inhibits cytokine signaling and cell adhesion.3

ALL, acute lymphoblastic leukemia; MM, multiple myeloma.

References
1. Moreau P, et al. Blood. 2012;120:947-959. 2. Kubiczkova L, et al. J Cell Mol Med. 2014;18:947-961. 3. Palumbo A, et al. N Engl J Med. 2011;364:1046-1060. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02303821. Accessed 4/15/21. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04191616. Accessed 9/10/20. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859427. Accessed 9/10/20.
Molecule
Modality4
Target4
Areas of Investigation5-7
Carfilzomib
Target4
PROTEASOME
Areas of Investigation5-7

ALL, acute lymphoblastic leukemia; MM, multiple myeloma.

References
1. Moreau P, et al. Blood. 2012;120:947-959. 2. Kubiczkova L, et al. J Cell Mol Med. 2014;18:947-961. 3. Palumbo A, et al. N Engl J Med. 2011;364:1046-1060. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02303821. Accessed 4/15/21. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04191616. Accessed 9/10/20. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859427. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.